ANRO

Alto Neuroscience Inc

22.87

Oct 30 • 11:15 AM ET -0.60 (-2.56%)

Healthcare Biotechnology USA Small NYSE

Peers: SPTX NMRA MPLT DFTX HELP RLMD AXSM DRUG VTGN MNOV

| Held by: VTI IWM VXF IWO IBB XPH DWAS SCHA VTWO PTH

Index	RUT
Market Cap	897.41M
Enterprise Value	676.97M
Income	-84.24M
Sales	0.00M
Book/sh	6.25
Cash/sh	6.21
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	68
IPO	Feb 02, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.66
P/C	3.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.85
Current Ratio	14.85
Debt/Eq	0.11
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-2.47
EPS next Y	-3.01
EPS next Q	-0.67
EPS this Y	-27.18%
EPS next Y	-7.91%
EPS next 5Y	-10.92%
EPS past 3/5Y	-26.47% -57.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	-3.04%
Sales Y/Y TTM	-
EPS Q/Q	1.28%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	11.50% -

Insider Own	9.40%
Insider Trans	-3.53%
Inst Own	79.57%
Inst Trans	6.42%
ROA	-40.90%
ROE	-49.17%
ROIC	-35.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.96%
SMA50	-19.13%
SMA200	-5.72%
Trades

Shs Outstand	39.24M
Shs Float	35.55M
Short Float	14.64%
Short Ratio	9.33
Short Interest	5.20M
52W High	37.48 -38.98%
52W Low	10.20 124.20%
Volatility	4.86% 6.35%
ATR (14)	1.50
RSI (14)	40.81
Beta	1.36
Rel Volume	0.55
Avg Volume	557.82K
Volume	93,278

Perf Week	4.09%
Perf Month	-9.65%
Perf Quarter	-16.14%
Perf Half Y	-8.31%
Perf YTD	28.48%
Perf Year	59.70%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.27
Target Price	38.88
Prev Close	23.47
Price	22.87
Change %	-2.56%

Consensus

Strong Buy

Avg. Price Target

$38.88

Implied Upside

+70.0%

Analysts11incl. previous ratings

Rating Distribution9 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 22, 2026	Initiated	WWolfe Research	Outperform
May 05, 2026	Initiated	BBofA Securities	Buy	$35	+53.0%
Jan 05, 2026	Resumed	CChardan Capital Markets	Buy	$30	+31.2%
Nov 17, 2025	Initiated	BBTIG Research	Buy
Sep 29, 2025	Initiated	CChardan Capital Markets	Buy	$15	-34.4%
Oct 23, 2024	Downgrade	WWedbush	Outperform → Neutral	$29 → $4	-82.5%
Oct 23, 2024	Downgrade	RRodman & Renshaw	Buy → Neutral
Sep 03, 2024	Initiated	WWedbush	Outperform	$29	+26.8%
Feb 27, 2024	Initiated	WWilliam Blair	Outperform
Feb 27, 2024	Initiated	TTD Cowen	Outperform
Feb 27, 2024	Initiated	SStifel	Buy	$32	+39.9%
Feb 27, 2024	Initiated	RRobert W. Baird	Outperform	$32	+39.9%
Feb 27, 2024	Initiated	JJefferies	Buy	$33	+44.3%

Sep-09-26 08:03AM	Alto Neuroscience Announces Participation in Upcoming Investor Conferences (Business Wire)
Aug-27-26 04:05PM	Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer (Business Wire)
Aug-12-26 04:03PM	Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights (Business Wire) +10.69%
Jul-13-26 07:47AM	Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock (Business Wire) +5.85%
Jun-15-26 08:03AM	Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia (Business Wire)
08:03AM	Loading…
May-28-26 08:03AM	Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors (Business Wire)
May-15-26 08:27AM	Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award (Business Wire)
May-13-26 07:03AM	Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights (Business Wire) -7.23%
May-11-26 04:05PM	Alto Neuroscience Announces Participation in Upcoming Investor Conferences (Business Wire)
May-04-26 08:03AM	Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting (Business Wire)
Apr-21-26 08:03AM	Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression (Business Wire) -6.37%
Apr-02-26 09:44AM	Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss (Investor's Business Daily) -7.39%
08:20AM	Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM (BioPharma Dive)
Apr-01-26 04:30PM	Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements (Business Wire)
Mar-23-26 11:14AM	Alto Neuroscience CFO Nick Smith on Firms $120 Million Private Placement (NYSE) -6.75%
07:03AM	Loading…
Mar-16-26 07:03AM	Alto Neuroscience Announces $120 Million Private Placement Financing (Business Wire) +9.12%
06:03AM	Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Mar-13-26 08:03AM	Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum (Business Wire)
Feb-26-26 12:07PM	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders (PR Newswire)
Feb-23-26 08:33AM	Alto Neuroscience Announces Participation in Upcoming Investor Conferences (Business Wire)
Feb-13-26 08:04AM	Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia (Business Wire)
Feb-03-26 08:27AM	Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment (Business Wire)
Jan-14-26 07:27AM	Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression (Business Wire)
Jan-13-26 08:00AM	Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology (Business Wire)
Dec-03-25 04:05PM	Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (Business Wire)
Nov-14-25 09:40AM	Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? (Zacks) +6.70%
Nov-12-25 07:57AM	Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire) +5.97%
Nov-11-25 08:55AM	NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days (PR Newswire) +5.18%
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks) +10.30%
09:55AM	How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99% (Zacks)
07:34AM	Loading…
Oct-28-25 07:34AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire) +11.18%
Oct-23-25 12:00PM	Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy (Zacks) +9.61%
09:55AM	Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect? (Zacks)
Oct-20-25 10:50AM	Alto shares double on plans to speed depression drugs development (BioPharma Dive) +80.92%
07:03AM	Alto Neuroscience Announces $50 Million Private Placement Financing (Business Wire)
07:01AM	Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting (Business Wire)
Oct-17-25 09:27AM	Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia (Insider Monkey)
Oct-03-25 07:34AM	Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia (Business Wire) +56.24%
Sep-18-25 04:33PM	Investors in Alto Neuroscience, Inc. (ANRO): Protect Your Rights - Contact Levi & Korsinsky Before September 19, 2025 (Newsfile) +7.59% -12.41%
Sep-16-25 08:45AM	Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO (PR Newswire)
Sep-12-25 03:26PM	Did You Lose Money on Alto Neuroscience, Inc. (ANRO)? Levi & Korsinsky Urges Investors to Act Before September 19, 2025 (Newsfile)
08:45AM	Shareholders of Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO (PR Newswire)
Sep-09-25 07:09AM	Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia (Business Wire)
Sep-04-25 09:59AM	Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO (PR Newswire)
Sep-03-25 01:37PM	Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO (Business Wire) -6.96%
Sep-02-25 04:49PM	Shareholders of Alto Neuroscience, Inc. (ANRO): Protect Your Rights Before September 19, 2025 - Contact Levi & Korsinsky (Newsfile) +5.43%
Aug-19-25 08:45AM	Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO (PR Newswire)
Aug-18-25 08:03AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire) +8.60%
Aug-15-25 09:15AM	Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO (PR Newswire)
Aug-13-25 04:10PM	Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
08:03AM	Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors (Business Wire)
Aug-08-25 08:45AM	Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO (PR Newswire)
Aug-04-25 09:17AM	Investors Urged to Contact Levi & Korsinsky for Information Before September 19, 2025 - Alto Neuroscience, Inc. (ANRO) (Newsfile)
Jul-29-25 10:23AM	Stifel Keeps Buy Rating on Alto Neuroscience (ANRO) (Insider Monkey)
Jun-30-25 08:03AM	Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression (Business Wire)
Jun-26-25 07:33AM	Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203 (Business Wire) -10.51%
Jun-04-25 05:16AM	Regeneron makes obesity push; Atai, Alto ink brain drug deals (BioPharma Dive) -6.84%
Jun-03-25 02:48PM	Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal (Benzinga)
06:03AM	Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway (Business Wire)
May-29-25 08:03AM	Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder (Business Wire)
May-28-25 08:03AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire) -5.23%
May-14-25 04:10PM	Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights (Business Wire) -7.17% +10.45%
Apr-28-25 08:03AM	Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach (Business Wire)
Apr-22-25 08:03AM	Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day (Business Wire)
Apr-08-25 10:15AM	Alto Neuroscience initiated with a Buy at H.C. Wainwright (TipRanks) -10.18%
Mar-20-25 04:10PM	Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Mar-13-25 09:00AM	Christopher Nixon Cox Named Chairman of High-Trend International Group (PR Newswire) -8.14%
Mar-02-25 06:15AM	Jefferies Predicts Up to ~500% Jump for These 2 Strong Buy Stocks (TipRanks)
Feb-25-25 08:03AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire) -5.47%
Feb-19-25 08:03AM	Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker (Business Wire)
Feb-13-25 05:01AM	Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy (Clinical Trials Arena)
Feb-12-25 08:03AM	Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial (Business Wire)
Jan-08-25 12:00PM	All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy (Zacks)
Dec-11-24 08:03AM	Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (Business Wire)
Nov-28-24 08:06AM	Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline (PR Newswire)
Nov-12-24 04:10PM	Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -7.02%
Nov-04-24 08:00AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire) -6.78%
Oct-24-24 08:32AM	Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout (TipRanks) -5.28%
Oct-23-24 01:36PM	Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform (Benzinga) -69.99%
08:03AM	Alto hits new low as depression drug flunks key test (BioPharma Dive)
07:32AM	Altos Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint (Clinical Trials Arena)
Oct-22-24 04:30PM	Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder (Business Wire)
Sep-05-24 09:27AM	15 Healthiest Countries in Asia (Insider Monkey) -5.07%
Sep-04-24 08:05AM	Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants (Business Wire)
Sep-03-24 08:05AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-24 04:05PM	Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +9.25% +6.01%
Jul-25-24 08:30AM	Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach (Business Wire)
Jul-16-24 07:30AM	Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder (Business Wire) +6.90%
Jul-12-24 01:58PM	Hedge Fund and Insider Trading News: David Tepper, Bill Ackman, Josh Friedman, Whale Rock Capital Management, 352 Capital, Alto Neuroscience Inc (ANRO), Lions Gate Entertainment Corp. (LGF), and More (Insider Monkey)
Jun-20-24 08:05AM	Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia (Business Wire)
Jun-18-24 08:05AM	Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year 2024 Bay Area Award Winner (Business Wire)
Jun-10-24 09:00AM	Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On (InvestorPlace) +5.33%
May-29-24 08:05AM	Alto Neuroscience to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:05AM	Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer (Business Wire)
May-14-24 10:54PM	ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 (InvestorPlace)
04:03PM	Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
May-09-24 08:05AM	Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences (Business Wire) +5.19%
Apr-23-24 08:05AM	Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia (Business Wire)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Apr-09-24 09:37AM	Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Nicholas Conrad	PRESIDENT AND CFO	Oct 02 '26	Option Exercise	2.32	55,000	127,600	79,060	Oct 05 04:59 PM
Smith Nicholas Conrad	PRESIDENT AND CFO	Sep 29 '26	Option Exercise	2.35	110,830	260,450	134,890	Oct 01 09:33 PM
Smith Nicholas Conrad	PRESIDENT AND CFO	Sep 30 '26	Option Exercise	2.35	24,056	56,532	48,116	Oct 01 09:33 PM
Smith Nicholas Conrad	PRESIDENT AND CFO	Sep 29 '26	Sale	26.58	110,830	2,946,150	24,060	Oct 01 09:33 PM
Smith Nicholas Conrad	PRESIDENT AND CFO	Sep 30 '26	Sale	25.82	24,056	621,097	24,060	Oct 01 09:33 PM
NICHOLAS SMITH	Officer	Sep 29 '26	Proposed Sale	26.66	134,886	3,596,061		Sep 29 04:23 PM

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Ph.D.Dr. Amit Etkin M.D.

CFO & PresidentMr. Nicholas C. Smith

Chief Operating OfficerMr. Michael C. Hanley M.B.A.

BComMr. Dan Segal B.Sc. (Hons)

General CounselMs. Erin R. McQuade J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANRO

Alto Neuroscience Inc

Upgrade your Finviz experience